본문 바로가기
KERD
논문KCI 등재

Effect of Gongjindan-gamibang on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (2) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan-gamibang 100 mg/kg, 3.5hr-intervals with 7-day Repeated Treatment -

강수진|이영준|박수진|한창현|구세광|송창현|김승모|이창형
대한예방한의학회 (Society of Preventive Korean Medicine)|2015.04|대한예방한의학회지 (Society of Preventive Korean Medicine)|제19권 제1호|pp. 145-159

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

PharmacokineticsDrug-drug interactionsRatRepeat oral doseGongjindan-gamibangSorafenib
주제분류한의학

초록

Objective : In the previous study, co-administration of Gongjindan-gamibang (GJD) with sorafenib increased oral bioavailability of sorafenib through augment the absorption, therefore, the effects of GJD co-administration on the pharmacokinetics of sorafenib were observed after single and 7-day repeated oral co-administration with 3.5 hr-intervals in the present study. Method : After 50 mg/kg of sorafenib treatment, GJD 100 mg/kg was administered with 3.5 hr-intervals. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of first and last 7th sorafenib treatment, and plasma concentrations of sorafenib were analyzed using LC-MS/MS methods. PK parameters of sorafenib (Tmax, Cmax, AUC, t1/2 and MRTinf) were analysis as compared with sorafenib single administered rats. Results : GJD markedly inhibited the absorption of sorafenib, from 1 hr to 24 hrs after end of first 3.5 hr-interval co-administration, the Cmax (-43.27%), AUC0-t (-56.29%) and AUC0-inf (-66.70%) of sorafenib in co-administered rats were dramatically decreased as compared with sorafenib single treated rats. However, GJD significantly increased the absorption of sorafenib, from 4 hr to 8 hrs after end of last 7th 3.5 hrinterval co-administration, the AUC0-t (34.08%) and AUC0-inf (37.31%) of sorafenib in co-administered rats were dramatically increased as compared with sorafenib single treated rats. Conclusion : Although GJD decreased the oral bioavailability of sorafenib through inhibition of gastrointestinal absorptions after end of first 3.5 hr-interval co-administration, it is observed that GJD increases the oral bioavailability of sorafenib as facilitated the absorption after end of last 7th repeated co-administration. Hence, the co-administration of GJD and sorafenib should be avoided in the combination therapy of sorafenib with GJD on anticancer therapy

Abstract

Objective : In the previous study, co-administration of Gongjindan-gamibang (GJD) with sorafenib increased oral bioavailability of sorafenib through augment the absorption, therefore, the effects of GJD co-administration on the pharmacokinetics of sorafenib were observed after single and 7-day repeated oral co-administration with 3.5 hr-intervals in the present study. Method : After 50 mg/kg of sorafenib treatment, GJD 100 mg/kg was administered with 3.5 hr-intervals. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of first and last 7th sorafenib treatment, and plasma concentrations of sorafenib were analyzed using LC-MS/MS methods. PK parameters of sorafenib (Tmax, Cmax, AUC, t1/2 and MRTinf) were analysis as compared with sorafenib single administered rats. Results : GJD markedly inhibited the absorption of sorafenib, from 1 hr to 24 hrs after end of first 3.5 hr-interval co-administration, the Cmax (-43.27%), AUC0-t (-56.29%) and AUC0-inf (-66.70%) of sorafenib in co-administered rats were dramatically decreased as compared with sorafenib single treated rats. However, GJD significantly increased the absorption of sorafenib, from 4 hr to 8 hrs after end of last 7th 3.5 hrinterval co-administration, the AUC0-t (34.08%) and AUC0-inf (37.31%) of sorafenib in co-administered rats were dramatically increased as compared with sorafenib single treated rats. Conclusion : Although GJD decreased the oral bioavailability of sorafenib through inhibition of gastrointestinal absorptions after end of first 3.5 hr-interval co-administration, it is observed that GJD increases the oral bioavailability of sorafenib as facilitated the absorption after end of last 7th repeated co-administration. Hence, the co-administration of GJD and sorafenib should be avoided in the combination therapy of sorafenib with GJD on anticancer therapy

참고문헌 (41)

  1. Bayer, "Nexavar (sorafenib tosylate) tablets prescribing information", ~ (2007)
  2. Smalley KS, "CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations", Oncogene, 28(1), pp.85~94 (2009)
  3. Ranieri G, "Sorafenib(BAY 43-9006)in hepatocellular carcinoma patients : from discovery to clinical development", Current medicinal chemistry, 19(7), pp.938~944 (2012)
  4. Koh YW, "Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro", Endocrine-related cancer, 19(1), pp.29~38 (2012)
  5. Dammrich DJ, "Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung : case report and review of literature", Journal of medical case reports, 5, pp.483~ (2011)
  6. Siegelin MD, "Sorafenib exerts anti-glioma activity in vitro and in vivo", Neuroscience letters, 478(3), pp.165~170 (2010)
  7. Alexandrescu DT, "Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib", Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(24), pp.4047~4048 (2008)
  8. McLellan B, "Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib", Dermatologic therapy, 24(4), pp.396~400 (2011)
  9. Ricciardi S, "Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells", Chemotherapy, 56(4), pp.303~312 (2010)
  10. Kupsch P, "Results of a phase I trial of sorafenib(BAY 43-9006)in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer", Clinical colorectal cancer, 5(3), pp.188~196 (2005)
  11. Di Gion P, "Clinical pharmacokinetics of tyrosine kinase inhibitors : focus on pyrimidines, pyridines and pyrroles", Clinical pharmacokinetics, 50(9), pp.551~603 (2011)
  12. Infante JR, "A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine", Cancer chemotherapy and pharmacology, 69(1), pp.137~144 (2012)
  13. Moretti LV, "Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin", American journal of health-system pharmacy : AJHP :official journal of the American Society of Health-System Pharmacists, 66(23), pp.2123~2125 (2009), American journal of health-system pharmacy
  14. Kim YH, "The effect of Kong Jin Dan on the lipid metabolism in rats fed high fat-diet", J East-West Med, 14, pp.61~78 (2001)
  15. 박치상, "拱辰丹의 성분 분석 및 抗酸化 작용에 미치는 영향", 대한본초학회지, 22(2), pp.51~63 (2007), 대한본초학회
  16. 성기문, "공진단이 MCAO모델 흰쥐에서 gliosis 억제에 미치는 영향", 대한한방내과학회지, 30(4), pp.674~684 (2009), 대한한방내과학회
  17. 황선미, "공진단이 CT105로 유도된 Alzheimer's disease 병태모델에 미치는 영향", 동의신경정신과학회지, 15(2), pp.103~118 (2004), 대한한방신경정신과학회
  18. 구세광, "Single Oral Dose Toxicity Test of Kong-Jin-Dan, a Polyherbal Formula in ICR Mice", Biomolecules & Therapeutics, 15(4), pp.245~251 (2007), 한국응용약물학회
  19. Sang-Nam Lee, "Micronucleus Test of Kong-Jin-Dan, a Polyherbal Formula, in Bone Marrow Cells of Male ICR Mice", 한국독성학회지, 24(3), pp.213~218 (2008), 한국독성학회
  20. 김승모, "Effect of Gongjindan, a Polyherbal Formula on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (1) - Single Oral Combination Treatment of Sorafenib 50mg", kg with Gongjindan 100mg, 대한예방한의학회지, pp.2014, 18(2)[DOI]
  21. Bailer AJ, "Testing for the equality of area under the curves when using destructive measurement techniques", Journal of pharmacokinetics and biopharmaceutics, 16(3), pp.303~309 (1988)
  22. Chiou WL, "Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve", Journal of pharmacokinetics and biopharmaceutics, 6(6), pp.539~546 (1978)
  23. Brose MS, "Rationale and design of decision : a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine(RAI)-refractory, differentiated thyroid cancer", BMC cancer, 11, pp.349~ (2011)
  24. Adjei AA, "Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review", Clinical lung cancer, 12(4), pp.212~217 (2011)
  25. Hainsworth JD, "Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme", Cancer, 116(15), pp.3663~3669 (2010)
  26. Tan W, "Anti-fatigue activity of polysaccharides extract from Radix Rehmanniae Preparata", International journal of biological macromolecules, 50(1), pp.59~62 (2012)
  27. 기성환, "Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis", Journal of Ginseng Research, 37(1), pp.45~53 (2013), 고려인삼학회
  28. Villarroel MC, "Plasma protein binding of sorafenib, a multi kinase inhibitor : in vitro and in cancer patients", Investigational new drugs, 30(6), pp.2096~2102 (2012)
  29. Kennoki T, "Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center", Japanese journal of clinical oncology, 41(5), pp.647~655 (2011)
  30. Clark JW, "Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors", Clinical cancer research : an official journal of the American Association for Cancer Research, 11(15), pp.5472~5480 (2005)
  31. Hornecker M, "Saturable absorption of sorafenib in patients with solid tumors : a population model", Investigational new drugs, 30(5), pp.1991~2000 (2012)
  32. Akaza H, "Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma", Japanese journal of clinical oncology, 37(10), pp.755~762 (2007)
  33. Furuse J, "Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma", Cancer science, 99(1), pp.159~165 (2008)
  34. Minami H, "Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors", Cancer science, 99(7), pp.1492~1498 (2008)
  35. Sparidans RW, "Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite", Journal of chromatography B, Analytical technologies in the biomedical and life sciences, 877(3), pp.269~276 (2009)
  36. Mross K, "Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor(RKI)BAY 43-9006 administered in combination with irinotecan(CPT-11)in patients with solid tumors", International journal of clinical pharmacology and therapeutics, 41(12), pp.618~619 (2003)
  37. Hu S, "Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters", Clinical cancer research : an official journal of the American Association for Cancer Research, 15(19), pp.6062~6069 (2009)
  38. Flaherty KT, "Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma : a phase I", II pharmacokinetic interaction study, 2011, pp.68(5), 1111~1118
  39. Dasanu CA, "Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma", Southern medical journal, 100(3), pp.328~330 (2007)
  40. Franck N, "Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib", Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(31), pp.e640~e642 (2010)
  41. Liang CP, "Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma", The British journal of dermatology, 165(2), pp.443~445 (2011)

관련 논문AI추천

Effect of Gongjindan, a Polyherbal Formula on the Pharmacokinetics Profiles of Sorafenib in Male SD Rats (1) - Single Oral Combination Treatment of Sorafenib 50mg/kg with Gongjindan 100mg/kg within 5min -강수진, 구세광, 김승모, 박수진, 송창현, 이영준, 이창형, 한창현대한예방한의학회 · 대한예방한의학회지2014 · 제18권 제2호Effects of the mixed formulation of sorafenib and blue honeysuckle on the pharmacokinetics profiles of sorafenib강수진, 강현구, 구세광, 이영준, 최성훈대한예방한의학회 · 대한예방한의학회지2019 · 제23권 제1호Effect of Gamiondam-tang (GMODT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with GMODT 100 mg/kg with 2.5 hr-intervals -강수진, 구세광, 류은아, 송창현, 이봉효, 이영준, 최성훈, 한창현대한예방한의학회 · 대한예방한의학회지2017 · 제21권 제2호Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated Co-administration곽민아, 구세광, 박성환, 박수진, 이영준대한예방한의학회 · 대한예방한의학회지2016 · 제20권 제2호Effect of the Single Oral Combination Treatment of Tamoxifen with Gamisoyo-san on the Pharmacokinetics Profiles of Tamoxifen구세광, 김주익, 이영준한의병리학회 · 동의생리병리학회지2020 · 제34권 제4호Effect of Gongjindan, a Traditional Korean Polyherbal Formula, on the Pharmacokinetics Profiles of Donepezil in Male SDRats (2) ― Single Oral Combination Treatment of Donepezil 10mg/kg with Gongjindan 100mg/kg, 1.5hr-intervals with 7-day Repeated Treatment ―구세광, 권오대, 박수진, 이영준, 정대규대한예방한의학회 · 대한예방한의학회지2013 · 제17권 제2호

이 간행물의 다른 논문 (12건)

1개 한의대 학생의 진로선택에 대한 인식과 태도 조사이재혁, 김지영pp. 1-10한의학 교육이 의대생의 한의학에 대한 태도에 미치는 영향손경진, 조임학, 임정화, 이정현, 윤영주pp. 11-22새로운 한의학 양생 범주에 관한 연구이영준, 임병묵, 박해모, 박선주, 현민경, 이해웅, 장보형, 이상재, 고성규, 신용철, 정명수, 황귀서, 김창희, 신헌태pp. 23-3333개국 대한민국 재외공관을 통한 전통의학 및 보완대체의학 관련 제도 조사박유리pp. 35-46경증 및 아임상 우울증의 중의학 임상연구 동향 분석 - China National Knowledge Infrastructure를 중심으로 -김상혁, 고유미, 이시우pp. 47-59
원문 보기